MediWound (MDWD) EBITDA (2013 - 2025)

MediWound's EBITDA history runs 13 years deep, the most recent figure standing at -$6.5 million for Q4 2025.

• On a quarterly basis, EBITDA fell 32.92% year-over-year to -$6.5 million in Q4 2025; TTM through Dec 2025 was -$21.6 million, a 35.85% decrease from a year earlier, with the FY2025 full-year figure at -$20.3 million, down 37.6% from the prior year.
• EBITDA eased to -$6.5 million in Q4 2025 per MDWD's latest filing, from -$5.4 million in the prior quarter.
• Across five years, EBITDA topped out at $3.4 million in Q4 2022 and bottomed at -$6.5 million in Q4 2025.
• The 5-year median for EBITDA is -$3.3 million (2023), against an average of -$3.3 million.
• Across the five-year window, EBITDA surged 219.93% in 2022 and plunged 194.54% in 2023, its largest moves.
• Year by year, EBITDA stood at -$2.9 million in 2021, then jumped by 219.93% to $3.4 million in 2022, then plunged by 194.54% to -$3.2 million in 2023, then slumped by 50.26% to -$4.9 million in 2024, then tumbled by 32.92% to -$6.5 million in 2025.
• Per Business Quant, the three latest MDWD EBITDA figures stand at -$6.5 million (Q4 2025), -$5.4 million (Q3 2025), and -$5.7 million (Q2 2025).